IBI is a specialty biopharma company that engages in the development and commercialization of novel intraocular therapeutics... Read more
IBI is a specialty biopharma company that engages in the development and commercialization of novel intraocular therapeutics... Read more
News
Oct 23, 2018
BioPortfolio
IBI: Icon Bioscience Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27092018 Prices from USD $250
Aug 24, 2018
BioPortfolio
IBI: Icon Bioscience Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250
Apr 01, 2018
BioPortfolio
IBI: BRIEFpSivida to buy eye products firm Icon Bioscience
Mar 30, 2018
VisionMonday
IBI: pSivida Acquires Icon Bioscience, Announces $60 Million Equity Financing
Feb 12, 2018
MassDevice
IBI: Icon Bioscience wins FDA nod for long-acting cataract surgery drug
Jun 26, 2017
BioSpace
IBI: ICON Annouces FDA Acceptance Of NDA Filing For DEXYCU, A Noval Drug Therapy For Treating Inflammation Associated With Cataract Surgery
Apr 17, 2017
PharmaLeaders
IBI: Icon Bioscience submits NDA to FDA for anti-inflammatory drug Dexycu
Apr 13, 2017
BioSpace
IBI: Icon Bioscience Submits NDA For DEXYCU, A Potential Transformational Drug Therapy For Treating Inflammation Associated With Cataract Surgery
Nov 14, 2016
NewsMaker
Press Release: IBI :
Retinoblastoma Therapeutics Drugs & Companies Pipeline Review, H2 2016
May 11, 2016
NewsMaker
Press Release: IBI :
Proliferative Diabetic Retinopathy (PDR) Therapeutic Pipeline Market Review, H1 2016
